###### Strengths and limitations of this study

-   The review indicates a paucity of data on the study objectives and heterogeneity in the timing of symptoms presentation in published studies.

-   Comprehensive search strategy was used to identify articles for this review.

-   This is the first review to identify the sequence and timing of the signs and symptoms in the early stage of Alzheimer's disease.

-   Dearth of data, heterogeneity in methodology and findings made it impossible to draw a definite conclusion.

-   Several other potential sources of heterogeneity like age, gender and education could not be investigated with the dearth of data.

Introduction {#s1}
============

Alzheimer's disease (AD), the most common type of dementia, is a devastating disease with multiple presentations. While the disease is associated with old age, scientists[@R1] have discovered that disease can develop at any age and the reason for this is unclear. The disease could develop before the age of 65 years, known as early-onset AD (EOAD), which might be inherited or sporadic, or after the age of 65 years, known as late-onset AD (LOAD), that accounts for 90% of all AD cases.[@R3] In the UK, a prevalence of 520 000 has been reported in 2014[@R4] with high individual, healthcare and financial burden.[@R7] There are challenges in diagnosing the disease early,[@R9] which can result to non-reversible symptoms progression, that lead to institutionalisation and high mortality rate among this group.[@R12] There is also the emotional and physical burden to the caregivers[@R13] as well as emotional, physical and financial burden to the healthcare system.[@R15] Even though there is discourse in the meaning of the early diagnosis, here, it refers to the diagnosis at the lowest threshold of the disease or at the stage of mild cognitive impairment (MCI), with cluster of early signs and symptoms and the diagnosis of the pathology of the disease before dementia. This is because the disease has a preclinical stage with the clinical symptoms yet evident but with changes in the brain and the risk of progression unknown, intermediate stage with mild cognitive and functional changes and dementia due to AD stage with severe cognitive and functional decline.

Among the reasons for the late diagnosis is that the signs and symptoms, at the early stages of AD, are sometimes not recognised and/or mistaken for signs of old age or symptoms of other conditions.[@R5] The above may be partly due to the fact that the timing and sequence of the early presentation of signs and symptoms are not reported by current studies.[@R19] Delaying onset of the disease by 5 years through early diagnosis and intervention could reduce the mortality rate of dementia (advanced stage of AD) by 30 000 yearly.[@R22]

This review attempts to answer the following research question: how far back from diagnosis and in what sequence do the first symptoms that warrant an AD diagnosis appear? Further understanding of the timing and the sequence of the presentation of signs and symptoms may enable practitioners to offer timely intervention.

Methods {#s2}
=======

Types of studies {#s2a}
----------------

All types of empirical studies were considered, excluding those of qualitative design.

Participants {#s2b}
------------

Included participants were aged between 30 and 85 years and diagnosed with AD.

Settings {#s2c}
--------

Primary care, memory clinics or secondary care settings.

Target condition {#s2d}
----------------

AD and any subtypes were diagnosed with the following tools: (a) National Institute of Neurological and Communicative Disorders and Stroke AD and Related Disorders Association (NINCDS-ADRDA, UK), a commonly used criteria for AD dementia; (b) National Institute on Aging-Alzheimer's Association (USA), a more recent criteria that use biomarkers to support the diagnosis; (c) Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV)[@R23]; and (d) DSM-5.[@R24]

Outcomes {#s2e}
--------

The outcomes of this review included (i) the sequence of presentation of the signs and symptoms that are indicative of AD prior to diagnosis,[@R20] (ii) the timing from the first reported symptom to diagnosis,[@R20] (iii) the timing from MCI to diagnosed dementia stage,[@R25] (iv) the timing of assessments leading up to a diagnosis of AD[@R26] and (v) the timing from clinical presentations to case fatality or death.[@R27]

Index symptoms {#s2f}
--------------

We used an index of early symptoms as a reference to ascertain the timing and sequence of events prior to disease presentation. The index is based on previous studies,[@R28] which includes apathy, agitation, anxiety, anosognosia, aberrant motor behaviour, acalculia, alexia, anomia, disinhibition, depression, irritability, hallucination and olfactory disturbances and weight loss.[@R28]

Exclusion criteria {#s2g}
------------------

-   Participants with other dementia or other neurological conditions;

-   Inaccurate diagnostic criteria;

-   Single index symptom;

-   Late-stage AD (AD dementia); a set of symptoms including memory loss, difficulty in thinking, problem solving or language difficulties.[@R33]

Search criteria for identification of studies {#s2h}
---------------------------------------------

We searched the literature via OvidSP MEDLINE (1950), PsycINFO (1887), British Nursing Index (1994), CINAHL (1937), PubMed central (2000) and the Cochrane register for diagnostic and intervention studies. We also used 'snowballing' and searched the references of relevant articles. Searches covered the period from 1937 to May 2016. No language or publication restrictions were applied. We used medical subject headings terms to standardise and improve the search; AD was the main term followed by the basic terms timing, onset and country, and the combination of terms. Details of the database search strategies are presented in online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}.
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###### Supplementary Appendix 1

Data collection and analysis {#s2i}
----------------------------

### Assessment of methodological quality {#s2i1}

The qualities of included studies were assessed using the QUADAS-2 tool, a methodological quality assessment tool used to assess diagnostic accuracy studies[@R34] ([table 1](#T1){ref-type="table"}) and PRISMA checklist. The tool consists of 14 items that rates the risk of bias, source of variations (applicability and reporting of quality), with each item rated as 'yes', 'no' or 'unclear', tailored under four domains that includes: participants selection; index test (signs and symptoms interpretation), reference standard (diagnostic criteria that correctly classify the target condition) and flow and timing (time interval and intervention between index test and reference standard).

###### 

Quality assessment using the QUADAS tool

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Domain                                                 Participant selection                                                                                                                     Index test                                                                                                Reference standard                                                                                                      Flow and timing of signs and symptoms
  ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Description                                            Describe methods of participant selection: included participants (prior testing, presentation, intended use of index test and setting).   Describe the index test (symptoms and signs) and how it was conducted and interpreted.                    Describe the reference standard and how it was conducted and interpreted.                                               Describe any participants who did not receive the index test(s) and/or reference standard (diagnostic criteria). Describe the time interval and any interventions between index test(s) and reference standard, that is, any intervention/medication given prior to diagnosis.

  Signalling questions (yes/no/unclear)                  Was a consecutive or random sample of participants enrolled?\                                                                             Were the index test results interpreted without knowledge of the results of the reference standard?\      Is the reference standard likely to correctly classify the target condition?\                                           Was there an appropriate interval between index test(s) and reference standard?\
                                                         Was a case-control design avoided?\                                                                                                       If a threshold was used, was it prespecified?                                                             Were the reference standard results interpreted without knowledge of the results of the index test?                     Did all participants receive a reference standard?\
                                                         Did the study avoid inappropriate exclusions?                                                                                                                                                                                                                                                                                                                               Did all participants receive the same reference standard?\
                                                                                                                                                                                                                                                                                                                                                                                                                                     Were all participants included in the analysis?

  Risk of bias (high/low/unclear)                        Could the selection of participants have introduced bias?                                                                                 Could the conduct or interpretation of the index test have introduced bias?                               Could the reference standard, its conduct or its interpretation have introduced bias?                                   Could the participant flow have introduced bias?

  Concerns regarding applicability: (High/low/unclear)   Are there concerns that the included participants do not match the review question?                                                       Are there concerns that the index test, its conduct, or interpretation differ from the review question?   Are there concerns that the target condition as defined by the reference standard does not match the review question?   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results {#s3}
=======

Results of the search {#s3a}
---------------------

The process by which articles were identified, screened and selected for the review is described in [figure 1](#F1){ref-type="fig"}. A total of 3528 articles were identified in the databases including 318 duplicates. Nine others were identified through hand searching, and 3179 were excluded based on the review of titles and abstract alone. The full-text versions of 40 were assessed for eligibility, 13 were initially included but 9 later excluded (reasons stated below). Four articles were finally included in the review.

![Flowchart indicating the process for the selection of studies. The flowchart indicates the articles identified through the search: those reviewed as title and abstract, those reviewed fully and the ones that met the inclusion criteria.](bmjopen-2016-015746f01){#F1}

Reasons for exclusion {#s3b}
---------------------

Although 13 studies were reviewed in full, 9 were excluded. The reasons for exclusion were: four studies were on unspecified dementia[@R30]; one study was undertaken in a developing country[@R38]; another on caregiver's distress[@R31]; one study was on a single case[@R22]; one study had incomplete data,[@R39] while another did not have a reference point for the diagnosis of AD.[@R19]

Summary of findings {#s3c}
-------------------

### Methodological quality of included studies {#s3c1}

The methodological quality in each domain was assessed individually.

The QUADAS-2 scores for each domain ([table 1](#T1){ref-type="table"}) of the studies included in the review are shown in [figures 2 and 3](#F2 F3){ref-type="fig"}. The reviewer included a nested case control with random sampling,[@R25] longitudinal follow-up of patients with MCI,[@R20] longitudinal prospective study of individuals at risk of autosomal dominant familial AD (FAD)[@R26] and a retrospective case study (postmortem).[@R27] For the case studies,[@R20] the exclusion criteria were appropriate and sample selection was consecutive, which reduced the risk of selection bias. ([table 2](#T2){ref-type="table"}, [figure 2](#F2){ref-type="fig"})

![Graph representing the risk of bias and applicability concerns. Each domain is represented as a percentage across included studies for the review; the red colour indicates high risk, while green indicates low risk. However, none of the studies were given an unclear risk of bias and applicability concerns (QUADAS-2 tool).](bmjopen-2016-015746f02){#F2}

![Summary of the risk of bias and applicability concerns. The reviewer's judgement on each domain for the included studies is shown with a high risk of bias and applicability concerns on index test for.[@R32]](bmjopen-2016-015746f03){#F3}

###### 

Summary of study methodology and key findings

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author(s) & year              Title of study                                                                                      Study objective                                                                                                                       Sample size   Study methods                                                                Key findings                                                                                                                                                                                                                                                                                                                                                                                                                                                    Strength                                                                                                                 Limitation                                                                                                                                     Statements
  ----------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Amieva *et al*, 2008[@R25]    Prodromal Alzheimer's disease: the successful emergence of clinical symptoms.                       To examine the emergence of the first clinical symptoms over a 14-year period of follow-up before dementia.                           350           A longitudinal nested case-control study.                                    Activities of daily living scores were the least to appear at 13--14 years of the study, MMSE scores remained the same until the 12th year, memory decline was reported 2 years into the study, closely followed the same year by cognitive decline and depressive symptoms, verbal decline in the 4th year and visual disturbance in the last 5--6 years into the study.                                                                                       Nested case control of a 14-year period, contributing to evidence on the long duration of the predementia phase.         The absence of an accurate measure of episodic memory. The composition of the study sample was heterogeneous.                                  The first symptom to appear was memory loss, followed by a cognitive decline, depression, visual disturbance and verbal memory loss; (0.05% point/year) from the 11 years.

  Devier *et al*, 2010[@R20]    Predictive utility of type and duration of symptoms at initial presentation in patients with MCI.   To assess (1) the duration and symptoms and (2) the impact of the symptoms on predicting conversion to AD.                            148           Longitudinal assessment, interviewing reliable informants to collect data.   Heterogeneity in the first symptom to appear with sequence and timing (average time in months) as follows: memory loss, 38.5; depressed mood, 37.4; performance, 36.8; personality, 32.5; behaviour, 31.1; language, 29.2; disorientation, 29.1; and psychosis, 14.0. For the converters, the average time from the onset of the first symptom to AD diagnosis was 62 months (a range from 19 to 176 months). Average time in the presentation was 62 months.   The provision of new information about the relationship of early symptoms in person presenting with cognitive decline.   A small number of converters within a group of EOAD. No detailed reports on the timing from first symptoms report to AD diagnosis.             Memory loss was reported as the first symptom in 80% of cases, depression in 9%, language deficit in 4%, cognitive changes in 2%, behavioural and personality changes in 1%.

  Fox *et al*, 1998[@R26]       Presymptomatic cognitive deficits in individuals at risk of familial AD.                            To assess the earliest clinical and neuropsychological features of familial AD.                                                       63            Case selection of asymptomatic at-risk members of early-onset familial AD.   The study suggests that memory decline is one of the earliest measurable cognitive deficits in AD, with the verbal memory more discriminating than the non-verbal. Cognitive decline was present 2--3 years before symptoms manifestation and 4--5 years before fulfilling the criteria for probable AD.                                                                                                                                                        The study demonstrates that cognitive deficits predict symptoms in familiar AD by several years.                         No comparison group. It was not possible to determine the exact point at which AD became clinically diagnosable within the 3-year follow-up.   7 subjects were left handed, 55 right handed and 1 ambidextrous.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Of the 63 subjects, 10 converted to AD with no difference in gender, age or left-handedness.

  Schmidt *et al*, 2010[@R27]   Clinical features of rapidly progressive AD.                                                        To examine the clinical features in terms of symptoms frequency, time span until onset and time point of onset relative to disease.   32            Retrospective case analysis.                                                 35 neurological, psychiatric and autonomic symptoms were identified in a rapid progressive AD, with a median time to survival being 26.4 months.                                                                                                                                                                                                                                                                                                                The study reported the symptom frequency, time span until onset and time point of onset relative to disease end point.   Fast-declining AD cases without control and few numbers of subjects, which could limit generalisation.                                         The most common symptoms reported were myoclonus (75%), disturbed gait (66%) and rigidity (50%). The sequence in the appearance of symptoms was disorientation, depression, impaired concentration, anxiety, disturbed gait, seizures, myoclonus and hallucination, consecutively; rigidity, sleep disturbance, apathy, weight loss and disinhibition.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer's disease; EOAD; early-onset AD; MMSE, mini-mental state examination.

The index test was not influenced by the reference standard in three studies.[@R20] However, the index test domain was judged as having a high risk of bias in a study[@R27] due to the fact that the index tests were interpreted based on the knowledge of the disease (postmortem). In the applicability concerns, the conduct and interpretation of the index symptoms were different from the review question in Fox *et al*[@R26] and Schmidt *et al*.[@R27] The Fox *et al*[@R26] study focused on the mean time from first assessment to the appearance of symptoms at reporting, while the study published by Schmidt *et al*[@R27] focused on identifying the median time span from clinical presentation of the disease to case fatality or death.

In the reference standard domain, all studies were undertaken using the diagnostic criteria for AD, recognised internationally that could correctly classify the condition with masking in all. The Schmidt *et al* study[@R27] on rapidly progressive AD (RPAD) was undertaken postmortem, the gold standard for the diagnosis of AD. However, none of the studies reported how the reference standard was operationalised or applied. They were assessed as being a low risk of concern about applicability.

In the flow and timing domain, there was an appropriate interval between the appearance of symptoms and signs and the reference standard. There was no mention of treatment in between the timings and all of the participants were diagnosed using the same reference standard. All participants were included in the analysis.

Findings {#s3d}
--------

### Outcome I {#s3d1}

Of the 148 participants in the Devier *et al* study,[@R20] 39 (26%) converted to AD and all of the converters were 55 years at baseline, indicating an EOAD. There were differences in the first symptom at presentation with memory decline reported as the first in 118 (80%) of the cases, depressed mood in 13 (9%), declined language in 6 (4%), change in performance of higher order/cognitive activities in 4 (3%), disorientation in 3 (2%), personality changes and behavioural changes in 2 (1%), with no group difference in symptoms reporting. Sequentially in the order of appearance of the signs and symptoms in all the participants, memory decline was the first followed by performance changes, changes in language, disorientation, personality changes, depressed mood, behavioural changes and psychosis, consecutively. However, for depression, reverse causality could be the case, as the history of depression with the first onset before the age of 60 years represents a risk of developing AD in later life[@R40] and all cause dementia.[@R41]

### Outcome II {#s3d2}

Memory decline was experienced in 38.5 months before diagnosis,[@R20] depressed mood in 37.4 months, performance in 36.8 months, personality changes in 32.5 months, behavioural changes in 31.1 months, language difficulties at 29.2 months, disorientation in 29.1 months and psychosis at 14.0 months prior to the diagnosis.

### Outcome III {#s3d3}

Amieva *et al*[@R25] study reported cognitive decline 12 years before dementia in a measure of semantic memory and conceptual formation. Depressive symptoms appeared concomitantly with the cognitive decline and followed 2 years later with verbal memory decline. Two years later, visual disturbances were recorded and worsened until the dementia stage.

### Outcome IV {#s3d4}

Of the 63 subjects in the Fox *et al*[@R26] study of autosomal dominant FAD, 10 converted to probably AD and the mean time (±SD) from first assessment to the appearance of symptoms was 2.6±1.4 years. Episodic memory loss was the most common and noticed on average 6 months before symptomatic assessment. The study suggests that cognitive decline is present 2--3 years before symptoms and 4--5 years before individuals fulfil the criteria for probably AD. There was no distinction in presentations with regards to age, gender and handedness. Verbal memory was superior to semantic memory in differentiating AD from normal ageing, with the lowest score in mini-mental state examination (MMSE) of 25 in a participant remaining stable for 2 years consistent with family members with the same score that remained healthy. This could help discriminate individuals at risk of conversion.

### Outcome V {#s3d5}

Thirty-five distinct neurological, psychiatric and autonomic symptoms and signs were identified in the Schmidt *et al*[@R27] study. The sequence and timing in months (averagely 26.4) of the presentation of the signs and symptoms were as follows: disinhibition, 51.1; spasticity, 31.1; dysphagia, 21.6; akinetic mutism, 20.0; significant weight loss, 20.0; apraxia, 19.5; apathy, 17.0; sleep disorder, 16.0; delusions, 15.0; myoclonus, hallucinations, seizures, 13.0; impaired concentration, 4.5; depression, 4.0; and disorientation, 2.0, with others following thereafter. A third of RPAD experienced rapid weight loss and sleep disorder, indicating their significance in discriminating the disease from other dementias.

Signs and symptoms {#s3e}
------------------

A pooled estimate was not possible to be reported due to the differences in participants, symptoms and types of AD, as well the scarcity of research that had reported on the sequence and timing of the early signs and symptoms. MCI was required at baseline in the Devier *et al* study,[@R20] with memory complaints 6 months to 10 years prior to enrolment. The study began long before the Petersen[@R42] MCI criteria definition. Prior to enrolment, memory loss was observed on average of 38.5; depressed mood, 37.4; performance, 36.8; personality, 32.1; behaviour deficits, 31.1; language deficits, 29.2; disorientation, 29.1 and psychosis, 14.0 months, before diagnosis.

For the 10 converters in the Fox *et al* study,[@R26] the mean time (±SD) from initial assessment to first symptomatic assessment was 3.1±1.5 years (range 1--5 years). The most common presentations were symptoms of very mild deficit in episodic memory. Two of the 10 subjects already had deficits in verbal memory and were the first to be symptomatic. Verbal memory deficit was observed 1--5 years during the symptomatic phase, indicating higher early sensitivity than the semantic memory and cognitive changes 2--3 years before the symptomatic phase. There was no difference observed between cases and non-converters in terms of age, gender, handedness or MMSE at initial assessment and symptomatic assessment.

In the Schmidt *et al*[@R27] study, the median disease duration was 26.4 months and the median age at clinical onset was 73 years. The authors were unable to obtain a summary of the data from the onset of the symptoms to disease diagnosis.

All the studies were diagnosed with the NINCDS-ADRDA diagnostic criteria and symptoms measured with the neuropsychiatry inventory score.

Discussion {#s4}
==========

Four studies met the inclusion criteria, which had heterogeneous objectives, diagnosis and participants. The four studies had a total of 593 people who were followed for conversion to AD. All the studies assessed the timing of the signs and symptoms of AD prior to a formal diagnosis and/or case fatality, but with different participants and type of AD.

Studies were assessed methodologically with the QUADAS-2 tool. Three of the included studies[@R20] validated their results via NINCDS-ADRDA and one study[@R27] via postmortem examination.

Even though there were differences in timing, objectives, participants and type of AD, the Fox *et al*[@R26] study on FAD identified a participant with an MMSE score of 25/30, the lowest in the group, that remained the same for 2 years, similar to family members that remained well throughout. This supports the evidence that MMSE offers a reasonably good diagnosis and classification of AD,[@R43] especially the accuracy of the MMSE baseline score. However, critics advised that the measurement should be interpreted with caution.[@R44] Furthermore, Schmidt *et al*[@R27] discovered additional focal neurological symptoms consistent with Creutzfeldt-Jacob disease (CJD); AD was misdiagnosed as CJD until the postmortem study proved AD as the cause of the presentations. This finding is in line with Mega *et al*[@R29] and Zahodne *et al*,[@R46] who reported that there are measurable behavioural changes in AD and suggested that focal neurological symptoms are associated with poor prognosis.[@R46]

Memory disturbances remain the predominant differentiating factor between early AD and normal ageing in all of the studies. Verbal memory was more vulnerable than non-verbal in the early-onset familial AD.[@R26] The memory test for words indicated significant differences in scores, 1--5 years before becoming symptomatic, against the notion of semantic memory vulnerability.

Depressed symptoms appeared at the same time as cognitive symptoms, and each of these was the first symptom to appear in some individuals with LOAD. However, memory loss presented early and frequently in this group too.[@R20] The rapidly progressive LOAD[@R42] presented predominantly with myoclonus (75%), disturbed gait (66%) and rigidity (50%). These symptoms were also early in the presentation process occurring before apathy. Neurological and depressive behavioural presentations are an early occurrence in EOAD.[@R20] This calls for further studies to identify the sequence and timing of the early signs and symptoms preceding the diagnosis, to aid the early detection and subsequent diagnosis of AD.

The main limitation of this systematic review was the dearth of data and heterogeneity in methodology and findings in the included studies. Moreover, pooled estimate or statistical analysis for the signs and symptoms was not possible to be calculated and several other potential sources of heterogeneity like the age of onset, gender and education could not be investigated given the paucity of relevant data.

We excluded studies on individual symptoms and signs, as well as other types of dementia, where it was not possible to isolate AD. Further and rigorous research is needed to understand the timing and sequence of the appearance of the signs and symptoms that elude to AD prior to diagnosis, with the aim of supporting as early an AD diagnosis as possible.

Conclusions {#s5}
===========

There is a proposition of multiple definitions including MCI and subjective cognitive decline to capture the intermediate stage between ageing and mild cognitive changes, which is in line with the effort to diagnose AD early, by recognising the signs and symptoms as reliable predictive markers of the disease.[@R46]

There are currently insufficient published data on the sequence and timing of the early signs and symptoms of AD. We advocate that more research should be undertaken in this area.

This review is important to general practitioners, researchers, health policymakers, the pharmaceutical industry and the public. The review is also of importance to neurologists and other practitioners dealing with dementing disorders.
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